References

tiblj

Туберкулез и болезни легких

Tuberculosis and Lung Diseases

2075-12302542-1506

Медицинские знания и технологии

10.21292/2075-1230-2020-98-1-54-61

tiblj-1388

Research Article

ОБЗОР

REVIEW

Лекарственная устойчивость M. tuberculosis (исторические аспекты, современный уровень знаний)

Drug resistance of M. tuberculosis (historical aspects, current level of knowledge)

Бурмистрова

И. А.

Burmistrova

I. A.

Бурмистрова Ирина Александровна - врач-фтизиатр.

127473, Москва, ул. Достоевского, д. 4

Irina A. Burmistrova - Phthisiologist.

4, Dostoevsky St., Moscow, 127473

Самойлова

А. Г.

Samoylova

A. G.

Самойлова Анастасия Геннадьевна - доктор медицинских наук, заместитель директора по научной работе.

127473, Москва, ул. Достоевского, д. 4

Anastasiya G. Samoylova - Doctor of Medical Sciences, Deputy Director for Research.

4, Dostoevsky St., Moscow, 127473

Тюлькова

Т. Е.

Tyulkova

T. E.

Тюлькова Татьяна Евгеньевна - доктор медицинских наук.

127473, Москва, ул. Достоевского, д. 4

Tatyana E. Tyulkova - Doctor of Medical Sciences.

4, Dostoevsky St., Moscow, 127473

Ваниев

Э. В.

Vaniev

E. V.

Ваниев Эдуард Владимирович - кандидат медицинских наук, заведующий амбулаторно-консультационным отделением.

127473, Москва, ул. Достоевского, д. 4

Eduard V. Vaniev - Candidate of Medical Sciences, Head of Out-Patient Consulting Department.

4, Dostoevsky St., Moscow, 127473

Баласанянц

Г. С.

Balasanyants

G. S.

Баласанянц Гоар Сисаковна - доктор медицинских наук, профессор.

194044, г. Санкт-Петербург, ул. Академика Лебедева, д. 6

Goar S. Balasanyants - Doctor of Medical Sciences, Professor.

6, Akademika Lebedeva St., St. Petersburg, 194044

Васильева

И. А.

Vasilyeva

I. A.

Васильева Ирина Анатольевна - доктор медицинских наук, профессор, директор.

127473, Москва, ул. Достоевского, д. 4

Irina A. Vasilyeva - Doctor of Medical Sciences, Professor, Director.

4, Dostoevsky St., Moscow, 127473

ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian Federation

ФГБ ВОУ ВПО «ВМА им. С. М. Кирова» МО РФРоссияS. M. Kirov Military Medical AcademyRussian Federation

2020

12022020

9815461

2020

Бурмистрова И.А., Самойлова А.Г., Тюлькова Т.Е., Ваниев Э.В., Баласанянц Г.С., Васильева И.А.

Burmistrova I.A., Samoylova A.G., Tyulkova T.E., Vaniev E.V., Balasanyants G.S., Vasilyeva I.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.tibl-journal.com/jour/article/view/1388

В обзоре приведены данные о частоте выявления микобактерий туберкулеза (МБТ) с лекарственной устойчивостью (ЛУ), а также об изменении спектра ЛУ в России и за рубежом с середины 50-х годов XX в. до настоящего времени. Наряду с известными механизмами формирования ЛУ МБТ, представлены новые исследования с описанием мутаций, сопряженных с наличием ЛУ.

The review presents data on the frequency of detection of drug resistant (DR) tuberculosis mycobacteria (MTB) as well as on the change in DR patterns in Russia and abroad from the mid-50s of the 20th century till the present. Along with the well-known mechanisms for DR MTB development, it tells about new research describing mutations associated with drug resistance.

туберкулезмикобактерии туберкулезалекарственная устойчивостьпротивотуберкулезные препаратыгенетические мутации

tuberculosismycobacterium tuberculosisdrug resistanceanti-tuberculosis drugsgenetic mutations

References1

Воробьева О. А. Лекарственная устойчивость микобактерий туберкулеза современный взгляд на проблему // Сибирский медицинский журнал. 2008. – № 2. – С. 5-8.

Vorobieva O.А. Drug resistance of Mycobacterium tuberculosis – current views on the problem. Sibirsky Meditsinsky Journal, 2008, no. 2, pp. 5-8. (In Russ.)

Воробьева О. А., Семечкина В. С. Особенности биологических свойств микобактерий туберкулеза, распространенных на территории Иркутской области // Бюллетень ВСНЦ СО РАМН. ‒ № 5. ‒ 2012. ‒ С. 32-34.

Vorobieva O.А., Semechkina V.S. Specific biological properties of tuberculosis mycobacteria prevalent in Irkutsk Region. Bulleten VSNTS SO RAMN, no. 5, 2012, pp. 32-34. (In Russ.)

Давыдов Н. С. Национальная стратегия Российской Федерации по предупреждению распространения устойчивости патогенных микроорганизмов к антимикробным препаратам: трудности и перспективы сдерживания одной из глобальных биологических угроз XXI века // БИОпрепараты. Профилактика, диагностика, лечение. ‒ 2018. ‒ Т. 18, № 1. ‒ С. 50-56. DOI: 10.30895/2221-996Х-2018-18-1-50-56.

Davydov N.S. The Russian Federation national strategy aimed to prevent the spread of antimicrobial resistance: the challenges and prospects of controlling the one of the global biological threats of the 21st century. Biopreparaty. Profilaktika, Diagnostika, Lechenie, 2018, vol. 18, no. 1, pp. 50-56. (In Russ.) doi: 10.30895/2221-996Х-2018-18-1-50-56.

Канищев В. В., Еремеева Н. И. Некоторые научно-практические аспекты эффективного использования в медицинских организациях дезинфицирующих средств без возможности адаптации к ним болезнетворных организмов // Дезинфекционное дело. ‒ 2017. № 4 (102). ‒ С. 41-48.

Kanischev V.V., Eremeeva N.I. Certain scientific and practical aspects of effective use of disinfectants in medical organizations preventing adaptation of organisms to these disinfectants. Dezinfektsionnoe Delo, 2017, no. 4 (102), Epub., pp. 41-48. (In Russ.)

Корецкая Н. М., Чушкина А. А., Наркевич А. Н. Динамика первичной лекарственной резистентности микобактерий при инфильтративном туберкулезе // Сибирское мед. обозрение. – 2013. – № 1. – С. 66-69.

Koretskaya N.M., Chushkina А.А., Narkevich А.N. Changes in primary drug resistance in case of infiltrative tuberculosis. Sibirskoye Med. Obozreniye, 2013, no. 1, pp. 66-69. (In Russ.)

Макаров И. Ю., Григоренко А. А., Андреева Л. П. Анализ структуры и тенденций развития лекарственной резистентности микобактерий туберкулеза на территории Амурской области. – 2003. – С. 50-52.

Makarov I.Yu., Grigorenko А.А., Аndreeva L.P. Аnaliz struktury i tendentsiy razvitiya lekarstvennoy rezistentnosti mikobakteriy tuberkuleza na territorii Аmurskoy oblasti. [Analysis of structure and tendencies in drug resistance development of tuberculous mycobacteria in Amur Region]. 2003, pp. 50-52.

Севастьянова Э. В., Шульгина М. В., Пузанов В. А., Мартынова Л. П. и др. Анализ лекарственной устойчивости микобактерий туберкулеза в экспериментальных регионах России, внедряющих программу ВОЗ по борьбе с туберкулезом // Пробл. туб. – 2002. – № 12. – С. 11-14.

Sevastyanova E.V., Shulgina M.V., Puzanov V.А., Martynova L.P. et al. Analysis of tuberculosis mycobacteria drug resistance in the pilot regions of Russia introducing WHO TB control program. Probl. Tub., 2002, no. 12, pp. 11-14. (In Russ.)

Томен К. Туберкулез: выявление и химиотерапия. Вопросы и ответы. Женева, 1980. – С. 114-132.

Toman K. Tuberkulez: vyyavleniye i khimioterapiya. Voprosy i otvety. [Russ. Edition of Toman's tuberculosis: case detection, treatment and monitoring. Questions and answers]. Geneva, 1980. pp. 114-132.

Уразова О. И. Молекулярно-генетические факторы туберкулеза легких // Бюллетень сибирской медицины. – 2010. – № 5. – С. 5-13.

Urazova O.I. Molecular genetic factors of pulmonary tuberculosis. Bulleten Sibirskoy Meditsiny, 2010, no. 5, pp. 5-13. (In Russ.)

Хоменко А. Г. Современные тенденции распространения туберкулеза в России // М.: РМЖ, 1998. – Т. 6, № 17. – С. 5.

Khomenko А.G. Current tendencies for tuberculosis transmission in Russia. Moscow, RMJ, 1998, vol. 6, no. 17, pp. 5. (In Russ.)

BabaiiKochaksareii M., Kaboosi H., Ghaemi E. A. MIRU-VNTR 15 loci capability in diagnosis of Beijing M. tuberculosis strains in comparison with Real Time PCR // Cell. Mol. Biol. (Noisy-le-grand). 2019. – Vol. 65, № 7.

BabaiiKochaksareii M., Kaboosi H., Ghaemi E. A. MIRU-VNTR 15 loci capability in diagnosis of Beijing M. tuberculosis strains in comparison with Real Time PCR. Cell. Mol. Biol. (Noisy-le-grand), 2019, vol. 65, no. 7.

Brossier F., Pham A., Bernard C., Aubry A., Jarlier V., Veziris N., Sougakoff; CNR-MyRMA. Molecular investigation of resistance to second-line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France // Antimicrob. Agents Chemother. ‒ 2017. – Vol. 61, № 2. pii: e01299-16. doi: 10.1128/AAC.01299-16.

Brossier F., Pham A., Bernard C., Aubry A., Jarlier V., Veziris N., Sougakoff; CNR-MyRMA. Molecular investigation of resistance to second-line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France. Antimicrob. Agents Chemother., 2017, vol. 61, no. 2. pii: e01299-16. doi: 10.1128/AAC.01299-16.

D'Ambrosio L., Migliori G. B., Sotgiu G. Time to review treatment of isoniazid-resistant tuberculosis? // Lancet Infect. Dis. – Vol. 17, Issue 2. P. 127-128.

D'Ambrosio L., Migliori G.B., Sotgiu G. Time to review treatment of isoniazid-resistant tuberculosis? Lancet Infect. Dis., vol. 17, issue 2, pp. 127-128.

Du Q., Long Q., Mao J., Fu T., Duan X., Xie J. Characterization of a novel mutation in the overlap of tlyA and ppnK involved in capreomycin resistance in Mycobacterium // IUBMB Life. 2014. – Vol. 66, № 6. ‒ Р. 405-414. doi: 10.1002/iub.1277.

Du Q., Long Q., Mao J., Fu T., Duan X., Xie J. Characterization of a novel mutation in the overlap of tlyA and ppnK involved in capreomycin resistance in Mycobacterium. IUBMB Life, 2014, vol. 66, no. 6, pp. 405-414. doi: 10.1002/iub.1277.

Elhassan M. M., Hemeg H. A., Elmekki M. A., Turkistani K. A., Abdul-Aziz A. A. Burden of multidrug resistant Mycobacterium tuberculosis among new cases in Al-Madinah Al-Monawarah, Saudi Arabia // Infect. Disord. Drug Targets. ‒ 2017. Vol. 17, № 1. ‒ Р. 14-23. doi: 10.2174/1871526517666161116104242.

Elhassan M.M., Hemeg H.A., Elmekki M.A., Turkistani K.A., Abdul-Aziz A.A. Burden of multidrug resistant Mycobacterium tuberculosis among new cases in Al-Madinah Al-Monawarah, Saudi Arabia. Infect. Disord. Drug Targets, 2017, vol. 17, no. 1, pp. 14-23. doi: 10.2174/1871526517666161116104242.

Groll A., Martin A., Jureen P., Hoffner S., Vandamme P., Portaels F., Palomino J. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB // P. Silva. Antimicrob. Agents Chemother. ‒ 2009. – Vol. 53, № 10. ‒ Р. 4498-4500.

Groll A., Martin A., Jureen P., Hoffner S., Vandamme P., Portaels F., Palomino J. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. P. Silva. Antimicrob. Agents Chemother., 2009, vol. 53, no. 10, pp. 4498-4500.

Günther G., van Leth F., Alexandru S., Altet N., Avsar K., Bang D., Barbuta R., Bothamley G., Ciobanu A., Crudu V., Davilovits M., Dedicoat M., Duarte R., Gualano G., Kunst H., de Lange W., Leimane V., Magis-Escurra C., McLaughlin A. M., Muylle I., Polcová V., Pontali E., Popa C., Rumetshofer R., Skrahina A., Solodovnikova V., Spinu V., Tiberi S., Viiklepp P., Lange C.; TBNET. Multidrug-resistant tuberculosis in Europe, 2010-2011 // Emerg. Infect. Dis. 2015. – Vol. 21, № 3. ‒ Р. 409-416. doi: 10.3201/eid2103.141343.

Günther G., van Leth F., Alexandru S., Altet N., Avsar K., Bang D., Barbuta R., Bothamley G., Ciobanu A., Crudu V., Davilovits M., Dedicoat M., Duarte R., Gualano G., Kunst H., de Lange W., Leimane V., Magis-Escurra C., McLaughlin A.M., Muylle I., Polcová V., Pontali E., Popa C., Rumetshofer R., Skrahina A., Solodovnikova V., Spinu V., Tiberi S., Viiklepp P., Lange C.; TBNET. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg. Infect. Dis., 2015, vol. 21, no. 3, pp. 409-416. doi: 10.3201/eid2103.141343.

Ignatyeva O., Balabanova Y., Nikolayevskyy V., Koshkarova E., Radiulyte B., Davidaviciene E., Riekstina V., Jaama K., Danilovits M., Popa C. M., Drobniewski F. A. Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries // Tuberculosis (Edinb). ‒ 2015. – Vol. 95, № 5. ‒ Р. 581-588. doi: 10.1016/j.tube.2015.05.018.

Ignatyeva O., Balabanova Y., Nikolayevskyy V., Koshkarova E., Radiulyte B., Davidaviciene E., Riekstina V., Jaama K., Danilovits M., Popa C. M., Drobniewski F. A. Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries. Tuberculosis (Edinb.), 2015, vol. 95, no. 5, pp. 581-588. doi: 10.1016/j.tube.2015.05.018.

Iseman M. D., Madsen L. A. Drug resistant tuberculosis // Clin. Chest Med. 1989. – Vol. 10. – P. 341-353.

Iseman M.D., Madsen L.A. Drug resistant tuberculosis. Clin. Chest Med., 1989, vol. 10, pp. 341-353.

Johansen S. K., Maus C. E., Plikaytis B. B., Douthwaite S. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs // Mol. Cell. ‒ 2006. – Vol. 23, № 2. ‒ Р. 173-182.

Johansen S.K., Maus C.E., Plikaytis B.B., Douthwaite S. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs. Mol. Cell., 2006, vol. 23, no. 2, pp. 173-182.

Khan M. T., Malik S. I., Ali S., Masood N., Nadeem T., Khan A. S., Afzal M. T. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan // BMC Infect. Dis. 2019. – Vol. 19, № 1. ‒ Р. 116. doi: 10.1186/s12879-019-3764-2.

Khan M.T., Malik S.I., Ali S., Masood N., Nadeem T., Khan A.S., Afzal M.T. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. BMC Infect. Dis., 2019, vol. 19, no. 1, pp. 116. doi: 10.1186/s12879-019-3764-2.

Li D., Wang J. L., Ji B. Y., Cui J. Y., Pan X. L., Fan C. L., Shao C. X., Zhao L. N., Ma Y. P., Zhang L. Z., Zhang C. L., Dong C. B., Hattori T., Ling H. Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, China // BMC Infect. Dis. ‒ 2016. – Vol. 16, № 1. Р. 516.

Li D., Wang J.L., Ji B.Y., Cui J.Y., Pan X.L., Fan C.L., Shao C.X., Zhao L.N., Ma Y.P., Zhang L.Z., Zhang C.L., Dong C.B., Hattori T., Ling H. Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, China. BMC Infect. Dis., 2016, vol. 16, no. 1, pp. 516.

Li H. C., Guo H. X., Chen T., Wang W., Wu Z. H., Chen L., Wu H. Z., Xu G. P., Chen X. X., Zhou L. Potential genes related to levofloxacin resistance in Mycobacterium tuberculosis based on transcriptome and methylome overlap analysis // J. Mol. Evol. ‒ 2020. – Vol. 9. doi: 10.1007/s00239-019-09926-z.

Li H.C., Guo H.X., Chen T., Wang W., Wu Z.H., Chen L., Wu H.Z., Xu G.P., Chen X.X., Zhou L. Potential genes related to levofloxacin resistance in Mycobacterium tuberculosis based on transcriptome and methylome overlap analysis. J. Mol. Evol., 2020, vol. 9. doi: 10.1007/s00239-019-09926-z.

Lin D., Wang W., Qiu F., Li Y., Yu X., Lin B., Chen Y., Lei C., Ma Y., Zeng J., Zhou J. Mass spectrometry-based identification of new serum biomarkers in patients with multidrug resistant pulmonary tuberculosis // Nan Fang Yi Ke Da Xue Xue Bao. ‒ 2019. – Vol. 39, № 12. ‒ Р. 1409-1420. doi: 10.12122/j.issn.1673-4254.2019.12.04.

Lin D., Wang W., Qiu F., Li Y., Yu X., Lin B., Chen Y., Lei C., Ma Y., Zeng J., Zhou J. Mass spectrometry-based identification of new serum biomarkers in patients with multidrug resistant pulmonary tuberculosis. Nan Fang Yi Ke Da Xue Xue Bao, 2019, vol. 39, no. 12, pp. 1409-1420. doi: 10.12122/j.issn.1673-4254.2019.12.04.

Lucarelli D., Vasil M. L., Meyer-Klaucke W., Pohl E. The Metal-Dependent Regulators FurA and FurB from Mycobacterium tuberculosis // Int. J. Mol. Sci. ‒ 2008. – Vol. 9, № 8. ‒ Р. 1548-1560. Epub 2008 Aug 28.

Lucarelli D., Vasil M.L., Meyer-Klaucke W., Pohl E. The Metal-Dependent Regulators FurA and FurB from Mycobacterium tuberculosis. Int. J. Mol. Sci., 2008, vol. 9, no. 8, pp. 1548-1560. Epub 2008 Aug 28.

Malik S., Willby M., Sikes D., Tsodikov O., Posey J. New insights into fluoroquinolone resistance in Mycobacte-rium tuberculosis: functional genetic analysis of gyrA and gyrB mutations // PLoS One. ‒ 2012. ‒ Vol. 7, № 6. ‒ Р. 1-10.

Mehmood A., Khan M. T., Kaushik A. C., Khan A. S., Irfan M., Wei D. Q. Structural dynamics behind clinical mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis associated with pyrazinamide resistance // Front Bioeng Biotechnol. ‒ 2019. – Vol. 7. ‒ Р. 404. doi: 10.3389/fbioe.2019.00404.

Mehmood A., Khan M.T., Kaushik A.C., Khan A.S., Irfan M., Wei D.Q. Structural dynamics behind clinical mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis associated with pyrazinamide resistance. Front Bioeng Biotechnol., 2019, vol. 7, pp. 404. doi: 10.3389/fbioe.2019.00404.

Mindru R., Spînu V., Popa C., Botezatu E., Spătaru R. Conventional and molecular diagnosis in a group of patients with drug-resistant tuberculosis // Pneumologia. ‒ 2014. – Vol. 63, № 3. ‒ Р. 168-173.

Mindru R., Spînu V., Popa C., Botezatu E., Spătaru R. Conventional and molecular diagnosis in a group of patients with drug-resistant tuberculosis. Pneumologia, 2014, vol. 63, no. 3, pp. 168-173.

Mitchinson D. A. How drug resistance emerges as a result of poor compliance during short course chemotherapy of tuberculosis // Int. J. Tuberc. Lung Dis. 1998. ‒ № 2. ‒ Р. 10-15.

Mitchinson D.A. How drug resistance emerges as a result of poor compliance during short course chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis., 1998, no. 2, pp. 10-15.

Mokrousov I., Otten T., Manicheva O., Potapova Y., Vishnevsky B., Narvskaya O., Rastogi N. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia // Antimicrob. Agents Chemother. ‒ 2008. Vol. 52, № 8. ‒ Р. 2937-2939.

Mokrousov I., Otten T., Manicheva O., Potapova Y., Vishnevsky B., Narvskaya O., Rastogi N. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob. Agents Chemother., 2008, vol. 52, no. 8, pp. 2937-2939.

Nguyen T. V. A., Anthony R. M., Bañuls A. L., Nguyen T. V. A., Vu D. H., Alffenaar J. C. Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention // Clin. Infect. Dis. ‒ 2018. – Vol. 66, № 10. ‒ Р. 1625-1630. doi: 10.1093/cid/cix992.

Nguyen T.V.A., Anthony R.M., Bañuls A.L., Nguyen T.V.A., Vu D.H., Alffenaar J.C. Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. Clin. Infect. Dis., 2018, vol. 66, no. 10, pp. 1625-1630. doi: 10.1093/cid/cix992.

Njire M., Tan Y., Mugweru J., Wang C., Guo J., Yew W., Tan S., Zhang T. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update // Adv. Med. Sci. ‒ 2016. – Vol. 61, № 1. ‒ Р. 63-71. doi: 10.1016/j.advms.2015.09.007.

Njire M., Tan Y., Mugweru J., Wang C., Guo J., Yew W., Tan S., Zhang T. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Adv. Med. Sci., 2016, vol. 61, no. 1, pp. 63-71. doi: 10.1016/j.advms.2015.09.007.

Nosova E., Bukatina A., Isaeva Y., Makarova M., Galkina K., Moroz A. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin // J. Med. Microbiol. ‒ 2013. ‒ Vol. 62, № 1. ‒ Р. 108-113.

Nosova E., Bukatina A., Isaeva Y., Makarova M., Galkina K., Moroz A. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J. Med. Microbiol., 2013, vol. 62, no. 1, pp. 108-113.

Pantel A., Petrella S., Matrat S., Brossier F., Bastian S., Reitter D., Jarlier V., Mayer C., Aubry A. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. ‒ 2011. ‒ Vol. 55, № 10. Р. 4524-4529.

Pantel A., Petrella S., Matrat S., Brossier F., Bastian S., Reitter D., Jarlier V., Mayer C., Aubry A. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2011, vol. 55, no. 10, pp. 4524-4529.

Pang Y., Lu J., Huo F., Ma Y., Zhao L., Li Y., Liang Q., Chu N., Gao M., Huang H. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review // J. Infect. ‒ 2017. – Vol. 75, № 5. ‒ Р. 433-440. doi: 10.1016/j.jinf.2017.08.005.

Pang Y., Lu J., Huo F., Ma Y., Zhao L., Li Y., Liang Q., Chu N., Gao M., Huang H. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review. J. Infect., 2017, vol. 75, no. 5, pp. 433-440. doi: 10.1016/j.jinf.2017.08.005.

Poce G., Biava M. Overcoming drug resistance for tuberculosis // Future Microbiol. ‒ 2015. – Vol. 10, № 11. ‒ Р. 1735-1741. doi: 10.2217/fmb.15.76.

Poce G., Biava M. Overcoming drug resistance for tuberculosis. Future Microbiol., 2015, vol. 10, no. 11, pp. 1735-1741. doi: 10.2217/fmb.15.76.

Rawat R., Whitty A., Tonge P. J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of inhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance // Proc. Natl. Acad. Sci. USA. ‒ 2003. Vol. 100. ‒ Р. 13881-13886.

Rawat R., Whitty A., Tonge P.J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of inhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. USA, 2003, vol. 100, pp. 13881-13886.

Singapore Tuberculosis Service / British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis // Am. Rev. Respir. Dis. ‒ 1979. ‒ № 119. ‒ Р. 579-585.

Singapore Tuberculosis Service / British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis., 1979, no. 119, pp. 579-585.

Shimao T. Drug resistance in tuberculosis control // Tubercle. ‒ 1987. – Vol. 68. Р. S5- S15.

Shimao T. Drug resistance in tuberculosis control. Tubercle, 1987, vol. 68, pp. S5- S15.

Sneha M. Pinto, Renu Verma, Jayshree Advani, Oishi Chatterjee, Arun H. Patil, Saketh Kapoor, Yashwanth Subbannayya, Remya Raja, Sheetal Gandotra T. S. Keshava Prasad Integrated Multi-Omic Analysis of Mycobacterium tuberculosis H37Ra Redefines Virulence Attributes Front. Microbiol., 19 June 2018. https://doi.org/10.3389/fmicb.2018.01314

Sneha M. Pinto, Renu Verma, Jayshree Advani, Oishi Chatterjee, Arun H. Patil, Saketh Kapoor, Yashwanth Subbannayya, Remya Raja, Sheetal Gandotra T.S. Keshava Prasad Integrated Multi-Omic Analysis of Mycobacterium tuberculosis H37Ra Redefines Virulence Attributes Front. Microbiol., 19 June 2018. https://doi.org/10.3389/fmicb.2018.01314

Talukdar D., Sharma R., Sharma A. K., Kumar R. Drug resistance in tuberculosis: how to counter the menace? // Curr. Pharm. Biotechnol. ‒ 2014. ‒ Vol. 15, № 12. ‒ Р. 1158-1165.

Talukdar D., Sharma R., Sharma A.K., Kumar R. Drug resistance in tuberculosis: how to counter the menace? Curr. Pharm. Biotechnol., 2014, vol. 15, no. 12, pp. 1158-1165.

Unissa A. N., Subbian S., Hanna L. E., Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis // Infect. Genet. Evol. ‒ 2016. – Vol. 45. ‒ Р. 474-492. doi: 10.1016/j.meegid.2016.09.004.

Unissa A.N., Subbian S., Hanna L.E., Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect. Genet. Evol., 2016, vol. 45, pp. 474-492. doi: 10.1016/j.meegid.2016.09.004.

Viswanathan G., Yadav S., Raghunand T. R. Identification of Mycobacterial genes involved in antibiotic sensitivity: implications for the treatment of tuberculosis with β-Lactam-containing regimens // Antimicrob. Agents. Chemother. ‒ 2017. – Vol. 61, № 7. pii: e00425-17. doi: 10.1128/AAC.00425-17.

Viswanathan G., Yadav S., Raghunand T.R. Identification of Mycobacterial genes involved in antibiotic sensitivity: implications for the treatment of tuberculosis with β-Lactam-containing regimens. Antimicrob. Agents, Chemother., 2017, vol. 61, no. 7. pii: e00425-17. doi: 10.1128/AAC.00425-17.

Yang J. S., Kim K. J., Choi H., Lee S. H. Delamanid, Bedaquiline, and Linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea // Ann. Lab. Med. ‒ 2018. – Vol. 38, № 6. ‒ Р. 563-568. doi: 10.3343/alm.2018.38.6.563. Erratum in: Ann Lab Med. 2019 Jan; 39(1):113.

Yang J.S., Kim K.J., Choi H., Lee S.H. Delamanid, Bedaquiline, and Linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann. Lab. Med., 2018, vol. 38, no. 6, pp. 563-568. doi: 10.3343/alm.2018.38.6.563. Erratum in: Ann Lab Med. 2019 Jan; 39(1):113.

World Health Organization. Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes. ‒ Geneva: World Health Organization, ‒ 1997. ‒ 108 pp.

World Health Organization. Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes. Geneva, World Health Organization, 1997, 108 p.

WHO/IUATLD global working group on antituberculosis drug resistance surveillance // Int. J. Tuberc. Lung Disease. – 1998. – Vol. 2, № 1. ‒ P. 72-89.

WHO/IUATLD global working group on antituberculosis drug resistance surveillance. Int. J. Tuberc. Lung Disease, 1998, vol. 2, no. 1, pp. 72-89.

WHO/IUATLD. Anti-tuberculosis Drug Resistance in the World. 2-nd Report. – Geneva, 2000

WHO/IUATLD. Anti-tuberculosis Drug Resistance in the World. 2-nd Report. Geneva, 2000.

WHO. Global TB report, 2019.

Zenteno-Cuevas R., Fernandez E., Viveros D., Madrazo-Moya C. F., Cancino-Muñoz I., Comas I., Gonzalez-Covarrubias V., Barbosa-Amezcua M., Cuevas-Cordoba B. Characterization of polymorphisms associated with multidrug-resistant tuberculosis by whole genomic sequencing: a preliminary report from Mexico // Microb. Drug. Resist. ‒ 2019. ‒ Dec 23. doi: 10.1089/mdr.2019.0054.

Zenteno-Cuevas R., Fernandez E., Viveros D., Madrazo-Moya C.F., Cancino-Muñoz I., Comas I., Gonzalez-Covarrubias V., Barbosa-Amezcua M., Cuevas-Cordoba B. Characterization of polymorphisms associated with multidrug-resistant tuberculosis by whole genomic sequencing: a preliminary report from Mexico. Microb. Drug. Resist., 2019, Dec. 23, doi: 10.1089/mdr.2019.0054.

Zhang Q., An X., Liu H., Wang S., Xiao T., Liu H. Uncovering the resistance mechanism of Mycobacterium tuberculosis to Rifampicin Due to RNA Polymerase H451D/Y/R Mutations From Computational Perspective Front Chem. ‒ 2019. ‒ Vol. 7. ‒ Р. 819. doi: 10.3389/fchem.2019.00819

Zhang Q., An X., Liu H., Wang S., Xiao T., Liu H. Uncovering the resistance mechanism of Mycobacterium tuberculosis to Rifampicin Due to RNA Polymerase H451D/Y/R Mutations From Computational Perspective. Front Chem., 2019, vol. 7, pp. 819, doi: 10.3389/fchem.2019.00819.

Zhang Y., Mitchison D. The curious characteristics of pyrazinamide: a review // Int. J. Tuberc. Lung Dis. ‒ 2003. ‒ Vol. 7, № 1. ‒ Р. 6-21.

Zhang Y., Mitchison D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis., 2003, vol. 7, no. 1, pp. 6-21.

Zimenkov D. V., Nosova E. Y., Kulagina E. V., Antonova O. V., Arslanbaeva L. R., Isakova A. I., Krylova L. Y., Peretokina I. V., Makarova M. V., Safonova S. G., Borisov S. E., Gryadunov D. A. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region // J. Antimicrob. Chemother. ‒ 2017. ‒ Vol. 72, № 7. ‒ Р. 1901-1906. doi: 10.1093/jac/dkx094.

Zimenkov D.V., Nosova E.Y., Kulagina E.V., Antonova O.V., Arslanbaeva L.R., Isakova A.I., Krylova L.Y., Peretokina I.V., Makarova M.V., Safonova S.G., Borisov S.E., Gryadunov D.A. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J. Antimicrob. Chemother., 2017, vol. 72, no. 7, pp. 1901-1906. doi: 10.1093/jac/dkx094.

https://rosrid.ru/ikrbs/form/4FUNHCU0JMXB9F9JJDMIUXMS

The authors declare that there are no conflicts of interest present.